Healthcare Analytical Testing Services Market: Emerging Trends in Pharmaceutical Quality Control
Every new drug, vaccine and medical device must prove it is
safe, stable and effective long before it reaches a patient, and the
laboratories that generate that proof have become a critical checkpoint in drug
development. According to Polaris Market Research, the global
Healthcare Analytical Testing Services Market was valued at USD 6.38
billion in 2023 and is projected to reach USD 16.10 billion by 2032, growing at
a CAGR of 10.8%.
The Shift: What's Actually Changing in Healthcare
Analytical Testing
Analytical testing has moved well beyond routine quality
checks. Providers now apply advanced analytical technologies to support disease
identification, prognosis and personalized patient care, while pharmaceutical
and biotech sponsors rely on the same services for drug development, efficacy
evaluation and regulatory compliance in preclinical and clinical trials.
AI-powered platforms are also turning biological testing data into refined
preclinical results, shortening the path from molecule to candidate. Applications
range from hospital and clinic diagnostics to specialized assays run by
contract research organizations and academic institutions, all aimed at better
patient outcomes. Those industry trends explain the double-digit market growth.
Healthcare Analytical Testing Services Market by the
Numbers
Analysts estimate the market size at USD 7.06 billion in
2024, on the way to a much larger figure:
- 2023
Market Size: USD 6.38 billion
- 2032
Projected Size: USD 16.10 billion
- CAGR
(2024–2032): 10.8%
👉 Want the full data
behind this shift? Get a Free Sample Report
Growth Drivers, Key Players and Market Segments to Watch
The expansion is being driven by faster technology adoption
and a surge in clinical trials — every trial needs testing for drug safety,
dosing, formulation, data integrity and quality control, and in July 2023
Broughton added Extractables and Leachables (E&L) testing to its analytical
portfolio — with key players including Charles River Laboratories,
Eurofins Scientific, LabCorp, and SGS shaping the competitive landscape across segments
such as By Type (bioanalytical testing, physical characterization, method
development and validation), By End-User, and By Region. Ongoing innovation by
pharmaceutical, biopharmaceutical and medical device companies keeps generating
new products that need testing.
Segment and Competitive Highlights
Bioanalytical testing, which covers drug quantification,
metabolite identification and pharmacokinetic analysis for vaccines, small
molecules and biologics, holds a considerable share. Pharmaceutical companies
were a leading end-user group in 2023, while medical device companies are
forecast to grow fastest as testing helps manufacturers manage product risk and
meet regulatory standards. Other top companies include ICON plc, Intertek, Pace
Analytical Services, PPD, Syneos Health and Toxikon. Deals are following
demand: Alliance Pharma announced its acquisition of U.K.-based Drug
Development Solutions in July 2025, and Merck invested €14 million in March
2024 to expand its Shanghai M Lab Collaboration Center. Cell-based assays are
another significant segment, prized in biomedical research and drug-discovery
screening because they measure cytotoxicity, biological activity and off-target
interactions while reflecting physiological conditions more accurately than
conventional biochemical assays. The type taxonomy is broad, also covering
batch-release, raw material, stability and microbial testing and genomics
services.
Challenges That Could Slow Growth
Cost is the main brake. Advanced instruments demand heavy
capital investment, stringent regulation adds compliance expense, and skilled
analysts are expensive to hire. That is why outsourcing decisions, and the
choice of a provider with the right scale and expertise, carry real weight.
North America Leads Today, but Europe Is Catching Up Fast
North America holds the largest share and is expected to
keep it, supported by demand from pharmaceutical, biopharmaceutical and medical
device companies and by rising investment in analytical services. Europe is
projected to be the fastest-growing region, as IoT-enabled devices, healthcare
applications and a surge in digital records drive adoption of advanced
analytics, delivering faster data-driven insights and helping lower healthcare
costs. These services provide a reliable source of accuracy, quality and
efficiency.
What This Means for Teams Tracking the Market Forecast
2032
For pharma sponsors, device makers and investors researching
the
Healthcare Analytical Testing Services market forecast 2032, the
underlying report breaks down company positioning, segment-level forecasts, and
regional opportunity through 2032 — useful context for any sourcing,
partnership, or investment conversation happening right now. Because the field
is fragmented and outsourcing continues to grow on cost considerations, the
competitive analysis can help teams choose partners and see where specialized
capabilities command a premium. Segment coverage runs from bioanalytical and
stability testing to microbial and genomics services, with end-user views
spanning pharmaceutical, medical device and biopharmaceutical firms, hospitals
and clinics, and forensic labs.
The Road Ahead
As pipelines expand and regulators demand ever more rigorous
data, analytical testing is set to become a strategic capability rather than a
checkpoint. Look for more acquisitions, laboratory expansions and AI-enabled
workflows, especially among providers that want to offer the full range from
bioanalytical to stability and microbial testing. Government initiatives that
encourage investment and innovation, along with companies entering new markets
that need customized testing, should keep demand rising.
More Trending Latest Reports By Polaris Market Research:
corrugated-plastic-sheets-a-sustainable-solution-for-modern-industry
rising-demand-driving-additive-manufacturing
Comments
Post a Comment